Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders: 2015-2025

Historic Net Income towards Common Stockholders for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' Net Income towards Common Stockholders fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.8 million, marking a year-over-year increase of 71.51%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Net Income towards Common Stockholders of -$19.5 million as of Q3 2025, which was down 29.41% from -$15.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Net Income towards Common Stockholders ranged from a high of $13.4 million in Q2 2022 and a low of -$196.7 million during Q4 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$36.7 million, with a median of -$19.5 million in 2025.
  • Per our database at Business Quant, Cartesian Therapeutics' Net Income towards Common Stockholders soared by 5,505.67% in 2022 and then slumped by 3,437.15% in 2023.
  • Cartesian Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at $12.2 million in 2021, then tumbled by 51.85% to $5.9 million in 2022, then plummeted by 3,437.15% to -$196.7 million in 2023, then spiked by 87.66% to -$24.3 million in 2024, then plummeted by 30.10% to -$19.5 million in 2025.
  • Its Net Income towards Common Stockholders was -$19.5 million in Q3 2025, compared to -$15.1 million in Q2 2025 and -$19.9 million in Q1 2025.